001     874656
005     20210130004736.0
024 7 _ |a 10.1016/j.clinph.2019.11.002
|2 doi
024 7 _ |a 0921-884X
|2 ISSN
024 7 _ |a 1388-2457
|2 ISSN
024 7 _ |a 1872-8952
|2 ISSN
024 7 _ |a 2128/24589
|2 Handle
024 7 _ |a altmetric:73668738
|2 altmetric
024 7 _ |a pmid:31901449
|2 pmid
024 7 _ |a WOS:000507859400021
|2 WOS
037 _ _ |a FZJ-2020-01572
082 _ _ |a 610
100 1 _ |a Lefaucheur, Jean-Pascal
|0 P:(DE-HGF)0
|b 0
|e Corresponding author
245 _ _ |a Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS): An update (2014–2018)
260 _ _ |a Amsterdam [u.a.]
|c 2020
|b Elsevier Science
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1585041604_3401
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a A group of European experts reappraised the guidelines on the therapeutic efficacy of repetitive transcranial magnetic stimulation (rTMS) previously published in 2014 [Lefaucheur et al., Clin Neurophysiol 2014;125:2150–206]. These updated recommendations take into account all rTMS publications, including data prior to 2014, as well as currently reviewed literature until the end of 2018. Level A evidence (definite efficacy) was reached for: high-frequency (HF) rTMS of the primary motor cortex (M1) contralateral to the painful side for neuropathic pain; HF-rTMS of the left dorsolateral prefrontal cortex (DLPFC) using a figure-of-8 or a H1-coil for depression; low-frequency (LF) rTMS of contralesional M1 for hand motor recovery in the post-acute stage of stroke. Level B evidence (probable efficacy) was reached for: HF-rTMS of the left M1 or DLPFC for improving quality of life or pain, respectively, in fibromyalgia; HF-rTMS of bilateral M1 regions or the left DLPFC for improving motor impairment or depression, respectively, in Parkinson’s disease; HF-rTMS of ipsilesional M1 for promoting motor recovery at the post-acute stage of stroke; intermittent theta burst stimulation targeted to the leg motor cortex for lower limb spasticity in multiple sclerosis; HF-rTMS of the right DLPFC in posttraumatic stress disorder; LF-rTMS of the right inferior frontal gyrus in chronic post-stroke non-fluent aphasia; LF-rTMS of the right DLPFC in depression; and bihemispheric stimulation of the DLPFC combining right-sided LF-rTMS (or continuous theta burst stimulation) and left-sided HF-rTMS (or intermittent theta burst stimulation) in depression. Level A/B evidence is not reached concerning efficacy of rTMS in any other condition. The current recommendations are based on the differences reached in therapeutic efficacy of real vs. sham rTMS protocols, replicated in a sufficient number of independent studies. This does not mean that the benefit produced by rTMS inevitably reaches a level of clinical relevance.
536 _ _ |a 572 - (Dys-)function and Plasticity (POF3-572)
|0 G:(DE-HGF)POF3-572
|c POF3-572
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef
700 1 _ |a Aleman, André
|0 P:(DE-HGF)0
|b 1
700 1 _ |a Baeken, Chris
|0 P:(DE-Juel1)131948
|b 2
700 1 _ |a Benninger, David H.
|0 P:(DE-HGF)0
|b 3
700 1 _ |a Brunelin, Jérôme
|0 P:(DE-HGF)0
|b 4
700 1 _ |a Di Lazzaro, Vincenzo
|0 P:(DE-HGF)0
|b 5
700 1 _ |a Filipović, Saša R.
|0 P:(DE-HGF)0
|b 6
700 1 _ |a Grefkes, Christian
|0 P:(DE-Juel1)161406
|b 7
700 1 _ |a Hasan, Alkomiet
|0 P:(DE-HGF)0
|b 8
700 1 _ |a Hummel, Friedhelm C.
|0 P:(DE-HGF)0
|b 9
700 1 _ |a Jääskeläinen, Satu K.
|0 P:(DE-HGF)0
|b 10
700 1 _ |a Langguth, Berthold
|0 P:(DE-HGF)0
|b 11
700 1 _ |a Leocani, Letizia
|0 P:(DE-HGF)0
|b 12
700 1 _ |a Londero, Alain
|0 P:(DE-HGF)0
|b 13
700 1 _ |a Nardone, Raffaele
|0 P:(DE-HGF)0
|b 14
700 1 _ |a Nguyen, Jean-Paul
|0 P:(DE-HGF)0
|b 15
700 1 _ |a Nyffeler, Thomas
|0 P:(DE-HGF)0
|b 16
700 1 _ |a Oliveira-Maia, Albino J.
|0 P:(DE-HGF)0
|b 17
700 1 _ |a Oliviero, Antonio
|0 P:(DE-HGF)0
|b 18
700 1 _ |a Padberg, Frank
|0 P:(DE-HGF)0
|b 19
700 1 _ |a Palm, Ulrich
|0 P:(DE-HGF)0
|b 20
700 1 _ |a Paulus, Walter
|0 P:(DE-HGF)0
|b 21
700 1 _ |a Poulet, Emmanuel
|0 P:(DE-HGF)0
|b 22
700 1 _ |a Quartarone, Angelo
|0 P:(DE-HGF)0
|b 23
700 1 _ |a Rachid, Fady
|0 P:(DE-HGF)0
|b 24
700 1 _ |a Rektorová, Irena
|0 P:(DE-HGF)0
|b 25
700 1 _ |a Rossi, Simone
|0 P:(DE-HGF)0
|b 26
700 1 _ |a Sahlsten, Hanna
|0 P:(DE-HGF)0
|b 27
700 1 _ |a Schecklmann, Martin
|0 P:(DE-HGF)0
|b 28
700 1 _ |a Szekely, David
|0 P:(DE-HGF)0
|b 29
700 1 _ |a Ziemann, Ulf
|0 P:(DE-HGF)0
|b 30
773 _ _ |a 10.1016/j.clinph.2019.11.002
|g Vol. 131, no. 2, p. 474 - 528
|0 PERI:(DE-600)1499934-1
|n 2
|p 474 - 528
|t Clinical neurophysiology
|v 131
|y 2020
|x 1388-2457
856 4 _ |y OpenAccess
|u https://juser.fz-juelich.de/record/874656/files/Lefaucheur_2020_Clin%20Neurophysiol_Evidence-based%20guidelines%20on%20the%20therapeutic%20use%20of%20repetitive%20transcranial%20magnetic%20stimulation%20%28TMS_%20An%20update.pdf
856 4 _ |y OpenAccess
|x pdfa
|u https://juser.fz-juelich.de/record/874656/files/Lefaucheur_2020_Clin%20Neurophysiol_Evidence-based%20guidelines%20on%20the%20therapeutic%20use%20of%20repetitive%20transcranial%20magnetic%20stimulation%20%28TMS_%20An%20update.pdf?subformat=pdfa
909 C O |o oai:juser.fz-juelich.de:874656
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 2
|6 P:(DE-Juel1)131948
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 7
|6 P:(DE-Juel1)161406
913 1 _ |a DE-HGF
|b Key Technologies
|l Decoding the Human Brain
|1 G:(DE-HGF)POF3-570
|0 G:(DE-HGF)POF3-572
|2 G:(DE-HGF)POF3-500
|v (Dys-)function and Plasticity
|x 0
|4 G:(DE-HGF)POF
|3 G:(DE-HGF)POF3
914 1 _ |y 2020
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
915 _ _ |a Creative Commons Attribution-NonCommercial-NoDerivs CC BY-NC-ND 4.0
|0 LIC:(DE-HGF)CCBYNCND4
|2 HGFVOC
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b CLIN NEUROPHYSIOL : 2017
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a WoS
|0 StatID:(DE-HGF)0110
|2 StatID
|b Science Citation Index
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
920 _ _ |l yes
920 1 _ |0 I:(DE-Juel1)INM-3-20090406
|k INM-3
|l Kognitive Neurowissenschaften
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-Juel1)INM-3-20090406
980 1 _ |a FullTexts


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21